GlassScriptPhysician profile
Julia K Ro
NPI 1912390428
$14,372.84
in general payments reported to CMS, 2019-2025
29 companies · $3,831 in 2025
The $3,831 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $967 · 2022: $763 · 2023: $3,834 · 2024: $4,978 · 2025: $3,831.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $279.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,363.73 |
| Education | $278.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,881.87 | 2021-2025 | |
| Dermavant Sciences, INC. | $1,410.63 | 2022-2024 | Vtama |
| Lilly USA, LLC | $1,311.75 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,242.47 | 2021-2025 | Tremfya |
| Ucb, INC. | $1,146.36 | 2021-2025 | Bimzelx, Cimzia, Briviact |
| E.R. Squibb & Sons, L.L.C. | $829.57 | 2022-2025 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $622.71 | 2023-2025 | Cabtreo, Jublia, Duobrii |
| Genzyme Corporation | $615.09 | 2021-2025 | |
| Galderma Laboratories, L.P. | $606.46 | 2021-2025 | Nemluvio, Aklief |
| Arcutis Biotherapeutics, INC. | $570.20 | 2023-2025 | Zoryve |
| Pfizer INC. | $562.41 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $506.12 | 2021-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $490.64 | 2021-2025 | |
| Incyte Corporation | $325.14 | 2021-2025 | Opzelura, Opzelura |
| Sun Pharmaceutical Industries INC. | $286.43 | 2021-2025 | Winlevi, Absorica Ld |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $282.08 | 2022-2025 | Adbry, Anzupgo |
| Amgen INC. | $114.33 | 2024-2025 | Otezla, Otezla |
| Organon LLC | $90.18 | 2025 | |
| Verrica Pharmaceuticals INC. | $82.48 | 2024 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $73.03 | 2022-2023 | Valchlor |
| Strata Skin Sciences, INC. | $68.22 | 2023-2025 | Xtrac |
| Botanix Sb INC | $56.14 | 2025 | Sofdra |
| Journey Medical Corporation | $43.09 | 2021-2025 | |
| Sebela Pharmaceuticals INC. | $39.67 | 2022 | |
| Vyne Pharmaceuticals INC. | $29.03 | 2021 | |
| Lnhc, INC | $24.26 | 2025 | Zelsuvmi |
| Biofrontera INC. | $21.57 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Mayne Pharma Commercial LLC | $20.92 | 2023 | |
| Cipher Pharmaceuticals US LLC | $19.99 | 2025 | Spinosad, Natroba |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Ro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.